Real-world data offers a glimpse into what happens to patients treated by real-world doctors under real-world circumstances, explained C.K. Wang, MD, senior medical director, COTA.
Real-world data offers a glimpse into what happens to patients treated by real-world doctors under real-world circumstances, explained C.K. Wang, MD, senior medical director, COTA.
Transcript
With limited patient populations involved in clinical trials, how can real-world data provide a more comprehensive picture of a drug’s efficacy?
There are many fundamental differences between clinical trial data and real-world data, or RWD. Clinical trial data essentially is the result of well-controlled scientific studies, and the patient that typically enrolls on a clinical trial is generally younger, more fit, and whiter than the general population. The real-world data, on the other hand, is essentially a glimpse into the information that currently exists in every provider’s office, and it constitutes patients from all ethnic backgrounds, socioeconomic status, and it gives us a very comprehensive view of what happens and essentially is a glimpse into what happens to patients treated by real-world doctors under real-world circumstances.
This insight that real-world data can give is very valuable or can be very valuable to life sciences companies in their attempts to help accelerate drug discovery and approval, as well as to monitor real-world treatment outcomes and treatment-related side effects. I think the best example of this is the most recent FDA approval, actually from yesterday, of a drug to treat a specific subtype of male breast cancer, which is a very rare cancer, and the study that led to this drug’s expanded approval essentially used real-world data in its study design. I think going forward, real-world data will be used more frequently to help life sciences companies to help accelerate their attempts to drug discovery and drug approval.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
New TROPiCS-02 Data Back Sacituzumab Govitecan for Older Patients With Breast Cancer
December 9th 2023This phase 3 study investigated sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, vs treatment of physician’s choice in pretreated patients who have endocrine-resistant hormone receptor–positive/HER2-negative breast cancer, the most common form of breast cancer.
Read More
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More